Bronchogen
Khavinson tetrapeptide bioregulator targeting bronchial and lung tissue — studied for respiratory function restoration and chronic obstructive pulmonary disease (COPD) support.
🔬 Mechanism of Action
Bronchogen (Ala-Glu-Asp-Leu, AEDL) is a synthetic tetrapeptide bioregulator targeting bronchial and pulmonary epithelium, derived from Khavinson's bronchial tissue peptide fractionation studies. The AEDL sequence was selected for its ability to normalize bronchial epithelial cell gene expression disrupted by chronic inflammation.
Bronchogen modulates gene expression for (1) mucin glycoproteins MUC5AC and MUC5B — the primary gel-forming mucins in airway mucus, (2) ciliary beat frequency regulation through DNAH5 and RSPH4A genes, and (3) secretory IgA production by submucosal glands. It also downregulates pro-inflammatory cytokines IL-8 and TNF-α in bronchial epithelium.
In COPD models, Bronchogen partially restored normal mucin ratios and improved mucociliary clearance rates. It is the synthetic counterpart to the Cytomax bronchial extracts Taxorest and Honluten.
Source: PMID: 15677927
📜Background & History
Bronchogen (AEDL) targets bronchial epithelium for respiratory health.
🎯 Research Use Cases
- ✓COPD support
- ✓Chronic bronchitis
- ✓Respiratory mucosal repair
💉 Dosing Protocol
| Typical Dose | 10-20 mg/day (oral) or 1-2 mg SC |
| Frequency | 1× daily for 10-30 day cycles |
| Half-Life | ~30 minutes (estimated) |
| Common Vial Sizes | 5 mg, 10 mg |
🧪 Reconstitution Example
⚠️Safety & Considerations
Standard Khavinson 10-30 day cycles. Can be combined with Taxorest (bronchial Cytomax) or Chonluten (lung tripeptide) for respiratory protocols.
⚡Interactions & Contraindications
Standard Khavinson protocol.
🔗Synergies & Common Stacks
Bronchogen (synthetic) + Taxorest (bronchial Cytomax) = layered respiratory support.
Bronchogen (bronchial epithelium) + Chonluten (alveolar/surfactant) = comprehensive lung bioregulator protocol.